Myconostica announces positive study results for MycAssay Pneumocystis and MycAssay Aspergillus assays; Exiqon reports positive results for MiRcury LNA Universal RT microRNA PCR test for colorectal cancer.
Exact Sciences, which licensed the intellectual property behind ColoSure to LabCorp, is developing a next-generation, multi-gene test for colorectal cancer and plans to start clinical trials later this year to support a premarket approval application with the FDA.
The test, which was launched in late 2009, detects methylated DNA of the Septin-9 gene, which Quest licensed from Epigenomics. It is targeted at people 50 years of age and above who should be screened for colon cancer but resist.
The service, which features a panel of 74 potential cancer protein biomarkers, uses the company's real-time PCR-based proximity ligation assay-based immunoassay platform to detect markers in plasma volumes as small as 2 microliters.
OncoTrack, a new international consortium, will seek to generate high-quality genomic and epigenetic data from clinically well-defined colon cancer tumors and their metastases as part of its colon cancer project.
The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.